1982
Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute
Anderson T, Chabner B, Young R, Berard C, Garvin AJ, Simon R, Devita V. Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute. Cancer 1982, 50: 2699-2707. PMID: 7139563, DOI: 10.1002/1097-0142(19821215)50:12<2699::aid-cncr2820501202>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsDiffuse lymphoma patientsNodular lymphoma patientsLymphoma patientsNational Cancer InstituteDiffuse lymphomaCancer InstituteCS III diseaseAdvanced-stage patientsBurkitt's lymphoma patientsExtranodal diseaseClinical stagingConsecutive patientsMedian agePathologic stagingStage patientsRetrospective reviewMalignant lymphomaNodular lymphomaSystemic symptomsRappaport systemPathologic materialBurkitt's lymphomaPatientsLymphomaDiseaseUndifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCases
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograft
1975
The American Burkitt Lymphoma Registry: a progress report.
Levine P, Connelly R, Berard C, O'Connor G, Dorfman R, EASTON J, DeVita V. The American Burkitt Lymphoma Registry: a progress report. Annals Of Internal Medicine 1975, 83: 31-6. PMID: 1147436, DOI: 10.7326/0003-4819-83-1-31.Peer-Reviewed Original ResearchConceptsLymphoma RegistryAfrican patientsAmerican patientsBurkitt's lymphomaEpstein-Barr virus titersPeripheral lymph node involvementAbrupt clinical presentationEpstein-Barr virus genomeHigh-dose cyclophosphamideLymph node involvementAmerican Burkitt's lymphomaCentral nervous systemPredominance of menPathologic reviewClinical presentationLymphocytic lymphomaAbsence of casesNonendemic regionsGastrointestinal tractNervous systemLymphomaPatientsVirus titersMore casesTime-space clusteringAmerican Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival
Arseneau J, Canellos G, Banks P, Berard C, Gralnick H, DeVita V. American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival. The American Journal Of Medicine 1975, 58: 314-321. PMID: 1115074, DOI: 10.1016/0002-9343(75)90597-5.Peer-Reviewed Original ResearchConceptsLDH levelsTumor massComplete remissionIU/Central nervous system involvementSerum lactic dehydrogenase levelsMonths of treatmentNervous system involvementSerum LDH levelsAmerican Burkitt's lymphomaResults of therapyLactic dehydrogenase levelsLarge tumor massParenteral cyclophosphamideClinical characteristicsClinicopathologic studyLocalized diseaseClinical factorsComplete responseFrequent siteSystem involvementTumor regressionDehydrogenase levelsSudden deathBurkitt's lymphomaAmerican Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations
Banks P, Arseneau J, Gralnick H, Canellos G, DeVita V, Berard C. American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations. The American Journal Of Medicine 1975, 58: 322-329. PMID: 163581, DOI: 10.1016/0002-9343(75)90598-7.Peer-Reviewed Original ResearchMeSH KeywordsAbdomenAdolescentAdultAutopsyBiopsyBone MarrowBurkitt LymphomaChildChild, PreschoolCytoplasmFemaleHumansInclusion BodiesIntestinal NeoplasmsIntestine, SmallLiverLymphatic MetastasisMacrophagesMaleMandibular NeoplasmsMaxillary NeoplasmsNorth AmericaOvarian NeoplasmsSouth AmericaUnited StatesConceptsMonths of therapyBone marrow involvementOlder median ageCentral nervous systemInitial therapyClinicopathologic studyMarrow involvementBurkitt's typeMedian ageMultiorgan involvementMalignant lymphomaShorter survivalMassive infiltrationAmerican patientsPelvic sitesPathologic correlationDiffuse necrosisHistologic appearanceTherapeutic implicationsOrgan sitesBone marrowNervous systemEndemic regionsTumor cellsLymphomaCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
Devita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAlkylating AgentsAntineoplastic AgentsBinding, CompetitiveBreast NeoplasmsBurkitt LymphomaChoriocarcinomaCyclophosphamideDrug ResistanceDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLeukemia, LymphoidNeoplasm MetastasisNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPregnancy
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activityRECENTLY RECOGNIZED COMPLICATIONS OF CANCER CHEMOTHERAPY
Arseneau J, Canellos G, DeVita V, Sherins R. RECENTLY RECOGNIZED COMPLICATIONS OF CANCER CHEMOTHERAPY. Annals Of The New York Academy Of Sciences 1974, 230: 481-488. PMID: 4595953, DOI: 10.1111/j.1749-6632.1974.tb14482.x.Peer-Reviewed Original Research
1973
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Sherins R, DeVita V. Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Annals Of Internal Medicine 1973, 79: 216-20. PMID: 4580112, DOI: 10.7326/0003-4819-79-2-216.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsBiopsyBurkitt LymphomaCyclophosphamideGerm CellsHodgkin DiseaseHumansLibidoLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNitrogen Mustard CompoundsPrednisoneProcarbazineRemission, SpontaneousSertoli CellsSpermatogenesisSpermatozoaTestisTime FactorsVincristine
1972
Treatment of the lymphomas.
DeVita V, Canellos G. Treatment of the lymphomas. Seminars In Hematology 1972, 9: 193-209. PMID: 4111886.Peer-Reviewed Original Research